Topics

Galapagos NV: MOR106 clinical development in atopic dermatitis stopped for futility

16:53 EDT 28 Oct 2019 | FinanzNachrichten

20.15 CET; regulated information - MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the end of the clinical developmen...

Original Article: Galapagos NV: MOR106 clinical development in atopic dermatitis stopped for futility

NEXT ARTICLE

More From BioPortfolio on "Galapagos NV: MOR106 clinical development in atopic dermatitis stopped for futility"

Quick Search